Literature DB >> 9326218

Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.

P Peeters1, S D Raynaud, J Cools, I Wlodarska, J Grosgeorge, P Philip, F Monpoux, L Van Rompaey, M Baens, H Van den Berghe, P Marynen.   

Abstract

Translocations in hematologic disease of myeloid or lymphoid origin with breakpoints at chromosome band 12p13 frequently result in rearrangements of the Ets variant gene 6 (ETV6). As a consequence either the ETS DNA-binding domain or the Helix-Loop-Helix (HLH) oligomerization domain of ETV6 is fused to different partner genes. We show here that a t(9;12)(p24;p13) in a case of early pre-B acute lymphoid leukemia and a t(9;15;12)(p24;q15;p13) in atypical chronic myelogenous leukemia in transformation involve the ETV6 gene at 12p13 and the JAK2 gene at 9p24. In each case different fusion mRNAs were found, with only one resulting in an open reading frame for a chimeric protein consisting of the HLH oligomerization domain of ETV6 and the protein tyrosine kinase (PTK) domain of JAK2. The cloning of the complete human JAK2 coding and genomic sequences and of the genomic junction fragments of the translocations allowed a characterization of the different splice events leading to the various mRNAs. JAK2 plays a central role in non-protein tyrosine kinase receptor signaling pathways, which could explain its involvement in malignancies of different hematologic lineages. Besides hop in Drosophila no member of the JAK family has yet been implicated in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326218

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  110 in total

Review 1.  Jaks and stats as therapeutic targets.

Authors:  J J O'Shea; R Visconti; T P Cheng; M Gadina
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  Tel, a frequent target of leukemic translocations, induces cellular aggregation and influences expression of extracellular matrix components.

Authors:  L Van Rompaey; W Dou; A Buijs; G Grosveld
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

3.  JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells.

Authors:  Shengming Zhao; Karen Zoller; Masayoshi Masuko; Ponlapat Rojnuckarin; Xuexian O Yang; Evan Parganas; Kenneth Kaushansky; James N Ihle; Thalia Papayannopoulou; Dennis M Willerford; Tim Clackson; C Anthony Blau
Journal:  EMBO J       Date:  2002-05-01       Impact factor: 11.598

4.  Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression.

Authors:  C A Kim; M L Phillips; W Kim; M Gingery; H H Tran; M A Robinson; S Faham; J U Bowie
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

Review 5.  Stat proteins and oncogenesis.

Authors:  Jacqueline Bromberg
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

6.  Lnk constrains myeloproliferative diseases in mice.

Authors:  Alexey Bersenev; Chao Wu; Joanna Balcerek; Jiang Jing; Mondira Kundu; Gerd A Blobel; Kudakwashe R Chikwava; Wei Tong
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

Review 7.  A potential role of ruxolitinib in leukemia.

Authors:  Kiran Naqvi; Srdan Verstovsek; Hagop Kantarjian; Farhad Ravandi
Journal:  Expert Opin Investig Drugs       Date:  2011-06-03       Impact factor: 6.206

8.  ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.

Authors:  D Smedley; A Demiroglu; M Abdul-Rauf; C Heath; C Cooper; J Shipley; N C Cross
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

9.  Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity.

Authors:  Zhe Li; Shu Xing; Shaofeng Wang; Wanting Tina Ho; Zhizhuang Joe Zhao
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

10.  Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target.

Authors:  Hideo Watanabe; Joshua M Francis; Michele S Woo; Banafsheh Etemad; Wenchu Lin; Daniel F Fries; Shouyong Peng; Eric L Snyder; Purushothama Rao Tata; Francesca Izzo; Anna C Schinzel; Jeonghee Cho; Peter S Hammerman; Roel G Verhaak; William C Hahn; Jayaraj Rajagopal; Tyler Jacks; Matthew Meyerson
Journal:  Genes Dev       Date:  2013-01-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.